The Pulmonary Hypertension Association will offer a free, regional workshop for people affected by pulmonary hypertension in Charlotte, North Carolina on Saturday, March 22. The PHA Connects: PH ...

Finding it hard to breathe when you lay down is medically called orthopnea. Find a list of potential causes to help narrow down your overall risk here.

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...

A new report from the Heart and Stroke Foundation shows that Canadians with congenital heart disease are living longer than ...